Objective. To increase the efficiency of chemoradiotherapy with dynamic accelerated hyperfractionation with concomitant boost for locally advanced cancer of larynx.

Materials and methods. A randomized prospective clinical trial included 150 men with the larynx squamous cell carcinoma, III and IVA, B stages. After evaluating the eligibility for inclusion in the study, all patients are randomly assigned to the main and the control groups. In the main group, chemoradiotherapy was performed by dynamic accelerated hyperfractionation with concomitant boost. In the control group, the conventional chemoradiotherapy was used.
A comparative analysis of the overall and cancer specific patient survivals was carried out.

Results. Statistically significant differences (p<0.001) of the 5-year overall and cancer-specific survival rates of patients of the main (55±6% and 68±6%, respectively) and in the control (13±4% and 17±5%, respectively) groups were revealed.

Conclusion. Using chemoradiotherapy with dynamic accelerated hyperfractionation with concomitant boost is an effective method of treating patients with locally advanced laryngeal cancer when compared with conventional chemoradiotherapy.